Prosecution Insights
Last updated: November 20, 2026
Application No. 17/932,633

Modified EC7 Cells Having Low Toxicity to Viral Production Payloads

Final Rejection §112
Filed
Sep 15, 2022
Priority
Oct 10, 2017 — provisional 62/570,508 +3 more
Examiner
MARVICH, MARIA
Art Unit
1634
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
NantWorks LLC
OA Round
2 (Final)
55%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
546 granted / 995 resolved
-5.1% vs TC avg
Strong +28% interview lift
Without
With
+27.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
66 currently pending
Career history
1058
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
27.4%
-12.6% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
36.2%
-3.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 995 resolved cases

Office Action

§112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This office action is in response to an amendment filed 9/25/2026. Claims 1-10 are pending in this application. This application is a divisional of US Patent Appl No.: 16/754,659, filed 04/08/2020 (now U.S. 11,485,967) which application is a 371 filing of PCT/US2018/054982 filed 10/9/2018 which claims priority to provisional application 62/570,508, filed 10/10/2017, and 62/633,412, filed 02/21/2018. The instant claimed subject matter was submitted with the claims of the PCT filing and therefore the effective filing date of the claims is 10/9/2018. Information Disclosure Statement An information disclosure statement filed 10/23/2026 has been identified and the documents considered. The corresponding signed and initialed PTO Form 1449 has been mailed with this action. The document initiated but crossed out has been considered. Response to Amendments The amendments are sufficient to overcome the objections to the claims and the rejections under 35 USC 112, second. Sequence Compliance This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, figures 9 and 15 contain sequences that are not identified by sequence identifier numbers. If the sequences can be found in the sequence listing it would be remedial to insert the appropriate SEQ ID NO:s. If not, a substitute paper copy of the “Sequence Listing”, as well as an amendment directing its entry into the specification, CRF and letter stating that the contents of the sequence listing and the CRF are the same and contain no new matter is required. Specifically, the letter stating that the contents of the sequence listing and the CRF are the same must state that there is no new matter by the submission of the sequence listing and CRF. A substitute paper copy of the “Sequence Listing”, as well as an amendment directing its entry into the specification, CRF and letter stating that the contents of the sequence listing and the CRF are the same and contain no new matter is required. Drawings Figure 9 is objected to under 37 CFR 1.83(a) because it fails to show any details as described in the specification. Specifically, figure 9 is cut off on the right end and is missing some of the text. Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d). A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance. Response to Arguments regarding the drawings and sequence compliance Applicants argue that the objections to the sequence compliance of the case as well as to the drawings is in error and alleges that the sequence is present in the drawings and the drawings are complete. The image provided for in the filing 10/17/2022 for Figures 9 and 15 are provided below. It is noted that these drawings reflect the latest submitted drawings on 10/17/2022. These images demonstrate that the images are incomplete. Claim 9 has 4 sequences that are not labeled below or the brief description of the figure. Claim 15 similarly does not include SEQ ID NO:s in this listing or the brief description of the figure. PNG media_image1.png 556 1050 media_image1.png Greyscale PNG media_image2.png 282 730 media_image2.png Greyscale Applicants cannot rely upon the filing of 9/15/2022 completely as Figure 9 is also cropped on the left side. PNG media_image3.png 386 746 media_image3.png Greyscale Claim Rejections - 35 USC § 112, first paragraph The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1-10 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This rejection is maintained for reasons below and extended to newly added claims. The instant claims are drawn a virus that quite broadly encodes any recombinant payload (related to claims 1-10). The claim specifies that the sequences encode an mRNA but any sequence whether RNA or DNA that encodes a protein will encode the mRNA. The RNA as claimed also comprises a 3’UTR comprising a shRNA binding site. Regarding the instant invention, the disclosure teaches construction of a test gene with a 3’ UTR site and a shRNA coding sequence. The targets were down-regulated. As to use, the disclosure teaches that the goal of the vector design is to increase titer and reduce expression of a viral payload gene in a host cell. One potential method is suppressing expression of a recombinant protein therein by including a binding site in the 3’ UTR (see ¶0014). This is creating a vector with conditional expression (see e.g. ¶0016). Discussion of the design is provided in terms of developing virus that do not express the payload in host cells provided for producing the virus as this can place and damper on production effects but the host cell (see e.g. ¶0051). Thereafter, the payload is expressed in cells wherein the expression is desired. “Entities” (shRNA inclusive) that are naturally present in a cell or genetically engineered to be expressed in a cell. The binding site are naturally present or engineered to be present in the mRNA of the payload (see e.g. ¶0052-0053). The goal is [0057] Regardless of the manner of suppressing expression of the payload of the recombinant virus, it is contemplated that suitable systems will afford a significantly improved uniformity in terms of yield and/or production time required to reach a predetermined quantity of therapeutic viral particles irrespective of the content and/or size of the payload. This is as related to the claims is depicted in figure 12 and described starting in ¶0065). PNG media_image4.png 494 1017 media_image4.png Greyscale In test cells, applicants demonstrated that they could downregulate expression of the “cargo”. While the general use is described in the disclosure, As will be appreciated, by housing these complementary target sequences in the 3'UTR of transgenes carried in the AdV5 genome, emerging transcripts are degraded thereby preventing any toxic effects of the would-be gene products. Most preferably, the shRNAs will be selected such that they do not recognize endogenous genes in the production cells. Moreover, it is further contemplated that recombinant constructs/host cells can be generated that express multiple (e.g., at least two, or at least three) different shRNAs along with the 3'UTRs that carry target sites for each of those shRNAs to so enhance the silencing potential. And host cells while generically referenced are described in terms of producer cells only. First, the only references when applied to host cells is to CHO, HEK293 and EC7 as producer cells (see e.g. ¶0012, 0015, 0047, 0073). Hence, the reference to patient cells is missing from the disclosure. Secondly, shRNA are generically referenced in the disclosure as tool to regulate expression. However, most specifically, the claims (related to claim 1-4) require a shRNA binding site absent in a patient cell. This requires knowing who the patient is, what cell is being referenced and then identification of the shRNA binding site. Furthermore, as the claims define the shRNA binding site as one that is absent in a patient cell to which the virus is administered. This complicates the nature of the claims as the claims are drawn to a product, the virus, and as the virus is not disinterred to patient one cannot know what the patient is or what the cell is. Applicants have not described any of these components. The claims lack adequate description to link structure to these required functions. The Court indicated that while applicants are not required to disclose every species encompassed by a genus, the description of a genus is achieved by the recitation of a precise definition of a representative number of members of the genus, such as by reciting the structure. Structural features that could distinguish the compounds of the claimed genus from others not encompassed by the genus are missing from the disclosure. In this case, there are specific elements referenced but the claims reference these structures with broad generic functional terms that represent a large and diverse genus of elements. But, the disclosure does not provide any of the structures. Response to Arguments The rejection above is based on the broad and generic nature of the claims. Specifically, as noted above by underlining, two components are broadly recited. In general to all the claims is the recitation of a shRNA and/or a shRNA binding site in terms of their function. In claims 1-4, 9 and 10, “a binding site for an shRNA that is absent in a patients cell to which the virus is administered” and in claims 6-8, this shRNA “reduces expression of a viral payload gene. As to patient, the rejection is based on the lack of structural guidance on what an shRNA that is absent in patient cell is. There is no guidance on the structure. Thus, applicants claim purports to cover all shRNA defined simply by being absent in a patient cell and teach none. The written description requirement for genus claims may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant identifying characteristics, i.e. structure or other physical and/or chemical properties, by functional characteristics coupled with known or disclosed correlations between function and structure, or by a combination of such characteristics sufficient to show that the applicant was in possession of the claimed genus. To this end, the MPEP provides such guidance (emphasis added). If the application as filed does not disclose the complete structure (or acts of a process) of the claimed invention as a whole, determine whether the specification discloses other relevant identifying characteristics sufficient to describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize applicant was in possession of the claimed invention. For example, if the art has established a strong correlation between structure and function, one skilled in the art would be able to predict with a reasonable degree of confidence the structure of the claimed invention from a recitation of its function. Thus, the written description requirement may be satisfied through disclosure of function and minimal structure when there is a well-established correlation between structure and function. In contrast, without such a correlation, the capability to recognize or understand the structure from the mere recitation of function and minimal structure is highly unlikely. In this latter case, disclosure of function alone is little more than a wish for possession; it does not satisfy the written description requirement. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406 (written description requirement not satisfied by merely providing "a result that one might achieve if one made that invention"); In re Wilder, 736 F.2d 1516, 1521, 222 USPQ 369, 372-73 (Fed. Cir. 1984) (affirming a rejection for lack of written description because the specification does "little more than outline goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate"). Compare Fonar, 107 F.3d at 1549, 41 USPQ2d at 1805 (disclosure of software function adequate in that art). The second issue, ” the shRNA reduces expression of any viral payload gene but also recites that the shRNA binds to a binding site on an mRNA encoded by a recombinant virus in the cells. As an initial issue with this claim, there is no linkage with the shRNA binding site and the payload gene. Even if the linkage between the payload gene and the mRNA encoded by the virus were made, this embraces a large and undefined genus of shRNA that bind to payload genes and to viral genes as this is not specified. Thus, claims 6-8 are drawn to any shRNA that reduces expression of any mRNA. To this end, applicants disclose a single structure in which “complementary” binding sites are inserted into a 3’ UTR. This means that a vector is designed with a specific shRNA binding site that is present in a cell to which the viral payload gene is introduced. As will be appreciated, by housing these complementary target sequences in the 3'UTR of transgenes carried in the AdV5 genome, emerging transcripts are degraded thereby preventing any toxic effects of the would-be gene products. Most preferably, the shRNAs will be selected such that they do not recognize endogenous genes in the production cells. Moreover, it is further contemplated that recombinant constructs/host cells can be generated that express multiple (e.g., at least two, or at least three) different shRNAs along with the 3'UTRs that carry target sites for each of those shRNAs to so enhance the silencing potential. However, the claim is not apparently drawn to this as detailed above. Hence, neither of the broadly claimed inventions (claims 1-4, 9 and 10) and claims 6-8 are adequately described in the disclosure to match the claims. The claims as presented simply embrace a large and undefined genus of desired functions. Applicants argue that claims 6-8 do not refer to patients and hence do not relate to the rejection. However, the rejection is based on claim language that refers to function without provision of structure in either the claims or the disclosure. Applicants argue that the claimed language can be found in the disclosure. However, the rejection is not based on the lack of language ipsis verbis but the lack of description of the genus of shRNA. Applicants argue that the binding molecule can be to any binding site on an RNA of the virus. But, the shRNA must also 1) be absent in a patient and 2) reduce expression of viral payload gene. This is especially problematic for claims 1-4, 9 and 10 as this shRNA is one the applicants must find. Applicants propose a functional property desired and ask practioners to find the corresponding molecule. Claim 4 provides for a binding site for luciferase, lacZ or beta lactamase. But it is not clear the relationship of these sequences to the payload, there is no reference to these sequences in the payload. TO identify the scope of claim 1, one must know what shRNA are absent in a patient cell and yet, the patient is not identified. This inherently means that this is a genus of shRNA that are not described in the disclosure. If applicants intend that the recombinant virus have a payload with a 3’ UTR with a binding site for luciferase, lacZ or beta-lactamase shRNA, these features should be added to the payload. But, this removes the notation that the shRNA must be absent in a patient cell which is a functional property that requires screening the patient cell. It is not clear that a virus with an shRNA binding site for luciferase, lacZ or beta-lactamase shRNA is not present in the art. However, this reads on a scope narrower than the instant claims. Regarding claims 6-8, modification to require that the shRNA binds to the payload mRNA and by this manner reduces expression of a viral payload gene provides a genus that it is argued lacks description for the genus of shRNA. The claims are drawn to a product and not a process and hence the requirement for description is such that one could know the genus of shRNA. While applicants profess to know which shRNA would mediate such function, there is no indication that applicants know what shRNA will perform said function. In the end, applicants have not completed any reasonable experiments and hence do not provide description of the invention. The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See Vas-Cath at page 1116). Structural features that could distinguish the compounds of the claimed genus from others not encompassed by the genus are missing from the disclosure. No common structural attributes identify the members of the genus. The general knowledge and level of skill in the art do not supplement the omitted description because specific, not general, guidance is needed. Since the disclosure fails to describe common attributes or characteristics that identify members of the genera, and because the genera are highly variant. In short, the claimed genus of virus and cells is not adequately described in the disclosure because the shRNA are claimed in broad unconnected terms and the actual structure is quite broad and diverse with only a single example for which the claims do not correspond. Closest prior art Jain et al teach vectors comprising toxic “payloads” that are modified by having miRNA sites in their 3’ UTR. The sites are selectively repressed based upon the cell type. Specifically, miR122 is repressed in hepatocellular carcinoma (see page 288, col 2). However, there is no indication that such regulation by shRNA would have been possible as the art does not teach shRNA binding sites that are not present in patient cells. This is a limited descriptive element wherein the claims broadly and incompletely claim the inventive elements and the disclosure does not provide requisite teachings to teach the full breadth of the claims. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARIA MARVICH whose telephone number is (571)272-0774. The examiner can normally be reached on 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached on 571-272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARIA MARVICH/Primary Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Sep 15, 2022
Application Filed
Jun 29, 2026
Non-Final Rejection mailed — §112
Sep 25, 2026
Response Filed
Nov 04, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799493
PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL
5y 7m to grant Granted Nov 17, 2026
Patent 12799469
COMPOSITIONS AND METHODS FOR TREATING CANCER
5y 5m to grant Granted Nov 17, 2026
Patent 12790382
Compositions and Methods for Treating Cancer with DuoCARs
4y 5m to grant Granted Nov 10, 2026
Patent 12758585
VACCINE COMPRISING NATURAL KILLER CELLS LOADED WITH LIGANDS OF NATURAL KILLER T CELLS AND CANCER ANTIGENS
1y 10m to grant Granted Oct 13, 2026
Patent 12760324
ENGINEERED MUSCLE TARGETING COMPOSITIONS
1y 12m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
55%
Grant Probability
83%
With Interview (+27.8%)
4y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 995 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month